Paladin Partners’s Pfizer PFE Stock Holding History

Paladin Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.93K	Hold	80	–	–	﹤0.01%	187
2026 Q1	$2.25K	Hold	80	–	–	﹤0.01%	180
2025 Q4	$1.99K	Buy	+80	New	+$2.02K	﹤0.01%	189

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Paladin Partners's PFE Position: Q2 2026 in Review

Paladin Partners held its Pfizer (PFE) position steady in Q2 2026 at 80 shares worth $1.93K. The position accounts for ﹤0.01% of the portfolio, ranked #187.

Paladin Partners first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.25K in Q1 2026. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Paladin Partners held 80 shares of Pfizer worth $1.93K as of Q2 2026.
Paladin Partners left its Pfizer share count unchanged in Q2 2026.
Pfizer made up ﹤0.01% of Paladin Partners's portfolio in Q2 2026, its #187 holding.
Paladin Partners first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
Paladin Partners's Pfizer position peaked at $2.25K in Q1 2026.
2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Paladin Partners's 13F filing for Q2 2026, filed 7 Aug 2026.